Analysts Issue Forecasts for MAZE Q2 Earnings

Key Points

• HC Wainwright has issued its Q2 2025 EPS estimate for Maze Therapeutics at ($1.15), maintaining a "Buy" rating with a price target of $34.00.
• The company's last reported earnings showed a loss of ($1.15) EPS, missing the consensus estimate by ($0.39).
• Maze Therapeutics has an average rating of "Buy" from analysts, with a consensus target price of $25.60.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Maze Therapeutics in a report issued on Wednesday, July 23rd. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings per share of ($1.15) for the quarter. HC Wainwright currently has a "Buy" rating and a $34.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics' Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($4.07) EPS, FY2028 earnings at ($1.92) EPS and FY2029 earnings at ($1.59) EPS.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

A number of other equities research analysts have also issued reports on the stock. Wedbush started coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. Guggenheim restated a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Stock Down 0.1%

Maze Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $16.81. 10,322 shares of the company's stock were exchanged, compared to its average volume of 204,147. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $19.19. The stock's fifty day simple moving average is $13.07.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund purchased a new position in Maze Therapeutics during the 1st quarter worth $25,000. CWM LLC purchased a new stake in shares of Maze Therapeutics in the second quarter valued at about $28,000. Corebridge Financial Inc. purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $57,000. Finally, Rhumbline Advisers purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $80,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.